Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lipid Lowering Medication Clear all
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 5, 2026, 9:19 PM EDT
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

NCT00263081
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
Drug
Lead sponsor
Takeda
Industry
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 5, 2026, 9:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

NCT06993597
View directory record Official record
Conditions
Glaucoma
Interventions
Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systems Biological Assessment of Statin Effect on Vaccine Responses

NCT06024096
View directory record Official record
Conditions
Vaccine Response
Interventions
Atorvastatin, Quadrivalent seasonal influenza vaccine
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

NCT01763827
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 3 Interventional

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

NCT00093249
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

NCT06423365
View directory record Official record
Conditions
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
Interventions
Virtual Statin Management (VSM)
Other
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 80 Years
Enrollment
898 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Recruiting Phase 2 Interventional

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

NCT06437574
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vytorin, Ezetimibe
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Reducing Risk Factors in Peripheral Arterial Disease

NCT00217919
View directory record Official record
Conditions
Cardiovascular Diseases, Peripheral Vascular Diseases
Interventions
Health-Counselor Mediated Telephone Counseling Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Implementation of Vascular Care Team to Improve Medical Management of PAD Patients

NCT04400409
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Intervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration, Intervention B - Standard Care + CPC EQuIP 6MWT administration
Other
Lead sponsor
Colorado Prevention Center
Other
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 2 Interventional

Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia

NCT00703274
View directory record Official record
Conditions
Stroke
Interventions
PROTECT DC
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 5, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

NCT06471036
View directory record Official record
Conditions
ASCVD, LDL-C
Interventions
Care Champion Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 2 Interventional

Lipitor as a Treatment for Alzheimer's Disease

NCT00024531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Institute for the Study of Aging (ISOA)
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 8, 2006 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 5, 2026, 9:19 PM EDT
Completed No phase listed Observational

Environmental Triggers Of Cardiometabolic Disease

NCT01548300
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Not listed
Lead sponsor
Sanjay Rajagopalan
Other
Eligibility
35 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 5, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Process Versus Outcomes Incentives for Lipid Management

NCT02246959
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease
Interventions
Process Incentive, Outcome Incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 5, 2026, 9:19 PM EDT